141 results on '"Htut, Than"'
Search Results
2. Live-cell imaging Unveils stimulus-specific dynamics of Nrf2 activation in UV-exposed melanoma cells: Implications for antioxidant compound screening
3. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
4. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma
5. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
6. Pathogenesis and Treatment of Usher Syndrome Type IIA
7. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
8. Sex-specific links between the social landscape and faecal glucocorticoid metabolites in semi-captive Asian elephants
9. Nutrient composition of 19 fish species from Sri Lanka and potential contribution to food and nutrition security
10. MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
11. Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development
12. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
13. Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
14. Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
15. Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
16. Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
17. SACCHAROMYCES CEREVISIAE SUBTYPE BOULARDII FUNGEMIA IN A PATIENT TREATED WITH A PROBIOTIC PREPARATION OF THE ORGANISM
18. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy
19. Mo1531 OUTCOMES OF EARLY TRANSPLANTATION FOR PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE
20. Expression phenotypes suggest that Der participates in a specific, high affinity interaction with membranes
21. Changes in reactive oxygen species begin early during replicative aging of Saccharomyces cerevisiae cells
22. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma
23. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.
24. Tolerability in Transplant-Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Based Combination Therapy: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
25. Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma
26. Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma
27. Incidence of Pneumonia, Sepsis and Febrile Neutropenia in Transplant-Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Based Combination Therapy: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
28. Efficacy and Tolerability of Luspatercept in Patients with Lower Risk Myelodysplastic Syndrome and Anemia: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
29. Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections and Febrile Neutropenia in Patients with Multiple Myeloma Treated with Isatuximab
30. Tolerability, Incidence of Second Primary Skin Malignancies and Diarrhea in Patients with Relapsed Refractory Multiple Myeloma Treated with Isatuximab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
31. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Lung Cancer Receiving Chemotherapy
32. Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
33. Efficacy of Isatuximab Combination Regimens in Patients with Relapsed and Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
34. BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
35. Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma
36. Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
37. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
38. Corrigendum to “Nutrient composition of 19 fish species from Sri Lanka and potential contribution to food and nutrition security” [J. Food Compos. Anal. 91 (2020) 103508]
39. P-347 Longitudinal profiling identifies genetic mechanisms of resistance to four different drug classes in a t(4;14) positive patient
40. P-131 Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): results of a phase 2 study
41. P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience
42. P-018 Prior BCMA-directed bispecific antibody or CAR T is not associated with increased risk of early infections in patients treated with bispecific antibodies
43. P-037 BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study
44. MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
45. POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
46. Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
47. Outcomes of Acute Myeloid Leukemia (AML) in Adolescents and Young Adults (AYAs) Compared to Adults in a Referral Center from Lower Myanmar
48. Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
49. Spinal epidural hematoma occurrence in the absence of known risk factors: A case series
50. Portoenterostomy for biliary atresia: long-term survival and prognosis after esophageal variceal bleeding
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.